

**ALPHACENTRIC LIFESCI HEALTHCARE FUND (LYFAX, LYFCX, LYFIX)**  
**SCHEDULE OF INVESTMENTS (Unaudited)**  
**June 30, 2023**

Shares		Fair Value
	<b>COMMON STOCKS — 98.4%</b>	
	<b>BIOTECH &amp; PHARMA - 82.7%</b>	
180,000	2seventy bio, Inc. <sup>(a)</sup>	\$ 1,821,600
50,000	ACADIA Pharmaceuticals, Inc. <sup>(a)</sup>	1,197,500
778,000	ADC Therapeutics S.A. <sup>(a)</sup>	1,672,700
35,000	Alkermes plc <sup>(a)</sup>	1,095,500
585,000	Amarin Corp plc - ADR <sup>(a)</sup>	696,150
132,500	Amicus Therapeutics, Inc. <sup>(a)</sup>	1,664,200
108,000	Amylyx Pharmaceuticals, Inc. <sup>(a)</sup>	2,329,560
292,500	Arcutis Biotherapeutics, Inc. <sup>(a)</sup>	2,787,525
2,250	Argenx S.E. - ADR <sup>(a)</sup>	876,893
50,000	Aurinia Pharmaceuticals, Inc. <sup>(a)</sup>	484,000
570,000	BioCryst Pharmaceuticals, Inc. <sup>(a)</sup>	4,012,800
16,500	BioMarin Pharmaceutical, Inc. <sup>(a)</sup>	1,430,220
15,000	Celldex Therapeutics, Inc. <sup>(a)</sup>	508,950
912,500	Coherus Biosciences, Inc. <sup>(a)</sup>	3,896,375
49,500	Collegium Pharmaceutical, Inc. <sup>(a)</sup>	1,063,755
47,000	Crinetics Pharmaceuticals, Inc. <sup>(a)</sup>	846,940
15,000	Cymbay Therapeutics, Inc. <sup>(a)</sup>	164,250
110,000	Day One Biopharmaceuticals, Inc. <sup>(a)</sup>	1,313,400
77,500	Deciphera Pharmaceuticals, Inc. <sup>(a)</sup>	1,091,200
110,000	Dynavax Technologies Corporation <sup>(a)</sup>	1,421,200
295,000	Elanco Animal Health, Inc. <sup>(a)</sup>	2,967,700
80,000	EQRx, Inc. <sup>(a)</sup>	148,800
33,000	Exelixis, Inc. <sup>(a)</sup>	630,630
99,000	Galapagos N.V. - ADR <sup>(a)</sup>	4,025,340
8,500	Gilead Sciences, Inc.	655,095
50,000	GSK plc - ADR	1,782,000
118,000	Harmony Biosciences Holdings, Inc. <sup>(a)</sup>	4,152,420
25,500	Horizon Therapeutics plc <sup>(a)</sup>	2,622,675
95,000	Insmed, Inc. <sup>(a)</sup>	2,004,500
25,500	Intra-Cellular Therapies, Inc. <sup>(a)</sup>	1,614,660
157,500	Ironwood Pharmaceuticals, Inc. <sup>(a)</sup>	1,675,800
63,000	iTeos Therapeutics, Inc. <sup>(a)</sup>	834,120
40,750	Jazz Pharmaceuticals plc <sup>(a)</sup>	5,051,777
135,000	KalVista Pharmaceuticals, Inc. <sup>(a)</sup>	1,215,000

**ALPHACENTRIC LIFESCI HEALTHCARE FUND**  
**SCHEDULE OF INVESTMENTS (Unaudited) (Continued)**  
**June 30, 2023**

Shares		Fair Value
	<b>COMMON STOCKS — 98.4% (Continued)</b>	
	<b>BIOTECH &amp; PHARMA - 82.7% (Continued)</b>	
810,000	Karyopharm Therapeutics, Inc. <sup>(a)</sup>	\$ 1,449,900
110,000	Kiniksa Pharmaceuticals Ltd. <sup>(a)</sup>	1,548,800
185,000	MorphoSys A.G. - ADR <sup>(a)</sup>	1,381,950
36,500	Neurocrine Biosciences, Inc. <sup>(a)</sup>	3,441,950
345,000	Nuvation Bio, Inc. <sup>(a)</sup>	621,000
56,500	Pacira BioSciences, Inc. <sup>(a)</sup>	2,263,955
130,000	Phathom Pharmaceuticals, Inc. <sup>(a)</sup>	1,861,600
70,000	Point Biopharma Global, Inc. <sup>(a)</sup>	634,200
28,500	Ultragenyx Pharmaceutical, Inc. <sup>(a)</sup>	1,314,705
47,500	uniQure N.V. <sup>(a)</sup>	544,350
9,000	United Therapeutics Corporation <sup>(a)</sup>	1,986,750
152,500	UroGen Pharma Ltd. <sup>(a)</sup>	1,578,375
150,000	Verastem, Inc. <sup>(a)</sup>	1,116,000
55,000	Verona Pharma plc - ADR <sup>(a)</sup>	1,162,700
55,000	Viatis, Inc.	548,900
35,500	Viridian Therapeutics, Inc. <sup>(a)</sup>	844,545
		<u>82,054,915</u>
	<b>HEALTH CARE FACILITIES &amp; SERVICES - 7.6%</b>	
282,500	AdaptHealth Corporation <sup>(a)</sup>	3,438,025
40,000	Centene Corporation <sup>(a)</sup>	2,698,000
39,000	Fulgent Genetics, Inc. <sup>(a)</sup>	1,444,170
		<u>7,580,195</u>
	<b>MEDICAL EQUIPMENT &amp; DEVICES - 4.3%</b>	
93,500	Embecka Corporation	2,019,600
23,000	Lantheus Holdings, Inc. <sup>(a)</sup>	1,930,160
4,000	Medtronic PLC	352,400
		<u>4,302,160</u>
	<b>RETAIL - CONSUMER STAPLES - 3.8%</b>	
95,000	PetIQ, Inc. <sup>(a)</sup>	1,441,150
80,000	Walgreens Boots Alliance, Inc.	2,279,200
		<u>3,720,350</u>
	<b>TOTAL COMMON STOCKS (Cost \$99,470,105)</b>	<u>97,657,620</u>

**ALPHACENTRIC LIFESCI HEALTHCARE FUND**  
**SCHEDULE OF INVESTMENTS (Unaudited) (Continued)**  
**June 30, 2023**

Shares		Expiration Date	Exercise Price	Fair Value
	<b>RIGHT — 0.0%</b> <sup>(b)</sup>			
	<b>BIOTECH &amp; PHARMA - 0.0%</b> <sup>(b)</sup>			
300,000	Amryt Pharma, Plc. – CVR <sup>(a) (d) (e)</sup>	12/31/2024	\$ 0.50	\$ –
300,000	Amryt Pharma, Plc. - CVR <sup>(a) (d) (e)</sup>	12/31/2024	\$ 0.50	–
	<b>TOTAL RIGHT (Cost \$0)</b>			<b>–</b>
	<b>SHORT-TERM INVESTMENTS — 3.0%</b>			
	<b>MONEY MARKET FUNDS - 3.0%</b>			
1	Fidelity Government Portfolio, Class I, 4.98% <sup>(c)</sup>			1
2,941,090	First American Treasury Obligations Fund, Class X, 5.03% <sup>(c)</sup>			2,941,090
	<b>TOTAL MONEY MARKET FUNDS (Cost \$2,941,091)</b>			<b>2,941,091</b>
	<b>TOTAL INVESTMENTS - 101.4% (Cost \$102,411,196)</b>			<b>\$ 100,598,711</b>
	<b>LIABILITIES IN EXCESS OF OTHER ASSETS - (1.4)%</b>			<b>(1,393,519)</b>
	<b>NET ASSETS - 100.0%</b>			<b>\$ 99,205,192</b>

ADR - American Depositary Receipt

CVR - Contingent Value Right

LTD - Limited Company

NV - Naamioze Vennootschap

PLC - Public Limited Company

S/A - Société Anonyme

<sup>(a)</sup> Non-income producing security.

<sup>(b)</sup> Percentage rounds to less than 0.1%.

<sup>(c)</sup> Rate disclosed is the seven day effective yield as of June 30, 2023.

<sup>(d)</sup> Illiquid security. The total fair value of these securities as of June 30, 2023 was \$0, representing 0.0% of net assets.

<sup>(e)</sup> Fair Valued by the Board of Trustees in good faith using significant unobservable inputs.